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Arg-Gly-Asp–binding integrins are critically involved in
cerulein-induced pancreatic ﬁbrogenesis in mice, a model of
chronic pancreatitis. Small-molecule Arg-Gly-Asp integrin
antagonists have the potential to be developed for effective
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http://dx.doi.org/10.1016/j.jcmgh.2016.03.004BACKGROUND & AIMS: Pancreatic stellate cells (PSCs) regu-
late the development of chronic pancreatitis (CP) and are acti-
vated by the cytokine transforming growth factor b (TGFB).
Integrins of the av family promote TGFB signaling in mice,
probably by interacting with the Arg-Gly-Asp (RGD) sequence of
the TGFB latency-associated peptide, which frees TGFB to bind
its cellular receptors. However, little is known about the role of
integrins in the development of CP. We investigated the effects
of small-molecule integrin inhibitors in a mouse model of CP.
METHODS: We induced CP in C57BL/6 female mice by
repeated cerulein administration. An active RGD peptidomi-
metic compound (Center for World Health and Medicine
[CWHM]-12) was delivered by continuous infusion, starting 3
days before or 5 days after cerulein administration began.
Pancreata were collected and parenchymal atrophy, ﬁbrosis,
and activation of PSCs were assessed by histologic, gene, and
protein expression analyses. We measured CWHM-12 effects on
activation of TGFB in co-culture assays in which rat PSC cells
(large T immortalized cells [LTC-14]) activate expression of a
TGFB-sensitive promoter in reporter cells.
RESULTS: Pancreatic tissues of mice expressed messenger
RNAs encoding subunits of RGD-binding integrins. Cerulein
administration increased expression of these integrins, altered
pancreatic cell morphology, and induced ﬁbrosis. The integrin
inhibitor CWHM-12 decreased acinar cell atrophy and loss, and
substantially reduced ﬁbrosis, activation of PSCs, and expression
of genes regulated by TGFB. CWHM-12 also reduced established
ﬁbrosis in mice and blocked activation of TGFB in cultured cells.
CONCLUSIONS: Based on studies of a mouse model of CP and
cultured PSCs, integrins that bind RGD sequences activate
PSCs and promote the development of pancreatic ﬁbrogenesis
in mice. Small-molecule antagonists of this interaction might
be developed for treatment of pancreatic ﬁbrotic diseases. (Cell
Mol Gastroenterol Hepatol 2016;2:499–518; http://dx.doi.org/
10.1016/j.jcmgh.2016.03.004)Keywords: Signal Transduction; Pancreas; Inﬂammation;
Peptidomimetic.
hronic pancreatitis (CP) is a slowly progressive dis-Cease that causes substantial loss of quality of life from
chronic pain, malnutrition, and diarrhea stemming from
exocrine insufﬁciency and ﬁnally endocrine insufﬁciency over
decades. The prevalence of CP is approximately 1/2000
persons, and patients with CP have a shortened survival
compared with the general population. Extensive pancreatic
ﬁbrosis is the primary pathologic feature of CP.1 No disease-
speciﬁc treatments are available, but a major advance in the
ﬁeld was the discovery of specialized cells in the pancreas,
named pancreatic stellate cells (PSCs), which are responsible
for the development of ﬁbrosis upon activation.2–4
The published literature strongly supports the central
importance of cytokine transforming growth factor b
(TGFB) in the activation of PSC and in driving pancreatic
ﬁbrogenesis.5 Triggering of the TGFB pathway is the pri-
mary regulatory mechanism found in several ﬁbroprolifer-
ative diseases including pulmonary ﬁbrosis and cirrhosis.6
TGFB initially is produced by cells in an inactive state
through association with latency-associated peptide (LAP)
and requires activation to produce its effects.7 The latent
complex is abundantly present in most tissues, including
the pancreas,8 and thus activation control may be a more
important mechanism of regulating its biological effects
than control of expression. Integrins of the av family bind
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implicated in TGFB activation in several organs.9–11 How-
ever, the mechanism of TGFB activation in pancreatic
ﬁbrogenesis has not been studied.
Integrins are a large family of transmembrane cell
adhesion and signaling receptors consisting of a and b
subunits connecting the inner cytoskeleton with the outer
extracellular matrix.12 In mammals, a total of 18 a and 8 b
integrin subunits noncovalently associate to form 24
different integrin heterodimers. This diversity and
complexity allows highly tissue-speciﬁc expression of
different heterodimers with different ligand afﬁnities. Of the
24 integrin heterodimers, 6 have been shown to bind and
activate latent TGFB in vitro by binding to the amino acid
sequence RGD of LAP.13–18 These include all av integrins
(avb1, avb3, avb5, avb6, and avb8) and a8b1.
The Center for World Health and Medicine (CWHM) at
Saint Louis University has synthesized many small-molecule
RGD peptidomimetic compounds that inhibit the ligand-
binding activities of integrins involved in TGFB activation.
One of these compounds, a broad range antagonist of
RGD-binding integrins called CWHM-12, recently was tested
in mouse models of lung and liver ﬁbrosis and showed
signiﬁcant efﬁcacy in ﬁbrosis prevention and reversal.11
The present studies evaluate the effects of pharmaco-
logic inhibition of RGD-binding integrins by CWHM-12 in a
cerulein-induced injury mouse model of CP. This model
reproduces the histopathologic features found in human CP,
including ﬁbrosis, inﬂammation, acinar atrophy, and tubular
complex formation.19–21 Moreover, the TGFB pathway was
shown to play a central role in ﬁbrosis development in this
model.22–24 We show a critical role of RGD-binding integrins
in CP and the promising potential to arrest or possibly even
reverse pancreatic ﬁbrosis using a pharmacologic approach
to inhibiting integrin-mediated TGFB activation.
Materials and Methods
Animals
Experiments were performed with C57BL/6 female 7- to
8-week-old mice obtained from the Jackson Laboratory
(Bar Harbor, ME). All mice were housed in standard facil-
ities under controlled conditions of temperature, humidity,
and a 12-/12-hour light/dark cycle, and were maintained on
standard rodent chow with free access to water. Animal care
and all procedures were approved by the Institutional
Animal Care and Use Committee of Saint Louis University.
Induction of Pancreatic Fibrosis and
Tissue Processing
Mice were divided randomly into treatment groups of 10
animals each. Pancreatic ﬁbrogenesis was induced by repeti-
tive intraperitoneal injections of 50 mg/kg cerulein (Sigma,
Saint Louis, MO) as described in detail previously.25–27 Brieﬂy,
cerulein treatments (one intraperitoneal injection every hour
for 6 hours) were given to mice every other day so that each
animal received 3 courses of the injury agent. The control
group received comparable injections of sterile 0.9% sodium
chloride (saline). Mice then were euthanized by CO2asphyxiation and this was performed 3 days after the last
injection to allow resolution of acute changes. Blood was
collected by cardiac puncture in heparin tubes (Lithium
Heparin Separator MiniCollect; Greiner Bio-One, Kremsi-
münster, Austria). The pancreas from each mouse was
removed, weighed, and divided into sections. Sections were
either immediately frozen in liquid nitrogen and stored at
-80C for subsequent protein extraction and Western blot
analysis, ﬁxed in 10% neutral buffered formalin solution
(Sigma) for histologic analysis, or placed in an RNA stabili-
zation solution (RNAlater; Ambion, Austin, TX) and stored
overnight at 4C for RNA isolation and subsequent real-time
quantitative polymerase chain reaction (PCR) assays.
Induction of Acute Pancreatic Injury and
Tissue Processing
Mice were divided into groups of 4–6 animals each. To
determine the effects of acute pancreatic injury, mice were
subjected to a single course of cerulein treatment (ie, 6
hourly intraperitoneal injections of 50 mg/kg each). Sex- and
age-matched control mice received comparable injections of
sterile saline solution. Nine hours after the ﬁrst injection,
the mice were euthanized by CO2 asphyxiation and blood
was collected by cardiac puncture for amylase analysis. Each
pancreas was removed, weighed, and placed in 10% neutral




The small-molecular-weight integrin antagonist,
CWHM-12, and its inactive enantiomer control compound,
CWHM-96, were synthesized by the Center for the World
Health and Medicine (Saint Louis University, St. Louis, MO).
Syntheses and structures of these compounds have been
described previously.11 This prior report also showed that
CWHM-12 has excellent potency (median inhibitory con-
centration [IC50] in the low nanomolar range) against 4 av
integrins (avb1, avb3, avb6, and avb8) and integrin a5b1 in
in vitro ligand-binding assays, and also has good but
somewhat lesser potency against avb5 (IC50 < 100 nmol/L).
In contrast, the R-isomer of CWHM-12, called CWHM-96,
which differs from CWHM-12 only in the orientation of its
carboxyl group, did not inhibit any of these integrins in
in vitro ligand-binding assays.11 To evaluate prevention of
pancreatic ﬁbrogenesis (preventive mode), CWHM-12 was
delivered by continuous infusion at 100 mg/kg/day (50%
dimethyl sulfoxide [DMSO], 50% phosphate-buffered saline
[PBS]) using Alzet mini-osmotic pumps (Durect, Cupertino,
CA) implanted subcutaneously in mice 3 days before the
ﬁrst cerulein treatment. Minipumps with vehicle (50%
DMSO, 50% PBS) also were implanted in cerulein-treated
and control saline-treated groups of mice. To evaluate the
effect of therapeutic rather than preventive compound
administration, minipumps with CWHM-12, CWHM-96, or
vehicle (for the cerulein- and saline-treated groups) were
implanted on day 5 (relative to the ﬁrst day of cerulein
treatment). To evaluate effects on acute pancreatic injury,
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(100 mL of 40 mg/mL CWHM-12 in 50% DMSO, 50% PBS,
pH 7.0) starting 1 hour before the ﬁrst cerulein injection,
and then twice more at the same dose at intervals of 3
hours. The control group of mice received intraperitoneal
injections of vehicle (50% DMSO, 50% PBS) in place of
compound.Real-Time Quantitative PCR
Isolation of total RNA frompancreatic tissue and real-time
quantitative PCR was conducted as we described previ-
ously.27 The primer sequences of transcripts evaluated by
quantitative PCR are listed in Table 1. PCR primers were
synthesized by Life Technologies (Carlsbad, CA) based on the
sequences from Primer Bank.28 Connective tissue growth
factor (CTGF) primers were designed using Primer Express
software (Applied Biosystems, Foster City, CA). Results were
calculated with normalization to ribosomal protein, large, P0
messenger RNA (mRNA). Ribosomal protein, large, P0 (also
known as acidic ribosomal phosphoprotein P0) was chosen
as the housekeeping control gene because it previously was
shown that its mRNA does not change signiﬁcantly with
single or multiple episodes of cerulein-induced pan-
creatitis.29–31 The comparative threshold cycle method 32
was used to calculate changes in mRNA abundance.Determination of CWHM-12 Concentration
in Plasma
Plasma samples (50 uL total volume) were diluted with
control naive mouse plasma as appropriate to bring sam-
ples into the range of the standard curve. The samples
were capped and mixed on a multiplate vortexer for 5
minutes and centrifuged for 5 minutes at 3200 rpm. The
supernatant was transferred to a 96-well sample plate and
capped for liquid chromatography–mass spectrometry and
















Rplp0, ribosomal protein, large, P0.(LC-MS-MS) analysis using a system consisting of a LC-
20AD pump (Shimadzu, Kyoto, Japan), an HTC PAL auto-
sampler (Leap Technologies, Carrboro, NC), and a Sciex
API-4000 mass spectrometer in ESI mode (AB Sciex, Foster
City, CA). An Amour C18 reverse-phase column (2.1  30
mm, 5 mm; Analytical Sales and Services, Pompton Plains,
NJ) was used for chromatographic separation. Mobile
phases were 0.1% formic acid (aqueous) and 100%
acetonitrile (organic) with a ﬂow rate of 0.35 mL/min. The
starting phase was 10% acetonitrile for 0.9 minutes,
increased to 90% acetonitrile over 0.4 minutes, main-
tained for an additional 0.2 minutes, returned to 10%
acetonitrile over 0.4 minutes, and then held for 1.6 mi-
nutes. The multiple reaction monitoring (MRM) transition
for CWHM-12 was as follows: mass/charge (m/z), 590.13
> 234.1. Peak areas were integrated using Analyst 1.5.1
(AB Sciex).
Histology Analysis
Formalin-ﬁxed pancreatic tissues were embedded in
parafﬁn, sectioned, and stained with H&E using standard
protocols for microscopic evaluation. Slides were graded by
an experienced pathologist (J.L.) masked to treatment
groups using a semiquantitative histopathology scoring
system. For the pancreatic ﬁbrosis experiments, slides were
scored as follows: within pancreatic sections the acinar
atrophy/loss was graded as follows: 0, absent; 1, 1%–5%; 2,
6%–15%; 3, 16%–35%; 4, 36%–50%; and 5, more than
50%; necrosis was scored as follows: 0, no necrosis; 1,
minimal (<10%); 2, moderate (10%–50%); and 3, severe
(>50%); tubular complex formation was scored as follows:
0, absent; 1, 1%–15%; 2, 6%–15%; 3, 16%–35%; 4, 36%–
50%; and 5, more than 50%. In addition, the presence of
acute inﬂammatory cells (mainly neutrophils) and chronic
inﬂammatory cells (mononuclear cells) was graded as
follows: 0, absent; 1, minimal; 2, mild; 3, moderate; and 4,
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graded on the following 4 criteria: vacuolization, necrosis,
inﬂammation, and edema. Vacuolization was graded as
follows: 0, absent; 1, 5%–14%; 2, 15%–35%; 3, 35%–50%;
and 4, more than 50%. Necrosis was graded as follows: 0,
absent; 1, periductal necrosis less than 5%; 2, focal necrosis
5%–20% (both periductal and parenchymal); and 3, diffuse
necrosis 20%–50%. Inﬂammation was graded as follows: 0,
absence of inﬂammatory inﬁltrates; 1, inﬂammatory inﬁl-
tration in ducts; 2, inﬂammatory inﬁltration in the paren-
chyma less than 50%; and 3, inﬂammatory inﬁltration in
the parenchyma more than 50%. Edema was graded as
follows: 0, absent; 1, focally increased between lobules; 2,
diffusely increased between lobules; and 3, acini disrupted
and separated. To evaluate pancreatic collagen content,
parafﬁn-embedded pancreatic sections were stained with
Sirius red as we have described previously.26 Pancreatic
sections from all mice were pretreated to remove parafﬁn
and stained with 0.1% Sirius red (F3B) solution in satu-
rated picric acid for 1 hour. Slides then were washed in 2
changes of 0.09 N acetic acid, dehydrated with 3 changes of
100% ethanol, cleared in xylene, and ﬁnally mounted in
Permaslip (Alban Scientiﬁc, Inc, St. Louis, MO). The degree
of collagen accumulation was assessed by morphometric
analysis33 using ImageJ software (version 1.37; National
Institutes of Health, Bethesda, MD) as we have detailed
previously.26 Brieﬂy, 8–12 nonoverlapping images (the
number of images needed to cover the whole section) from
each pancreatic section were captured using a Leica
DM4000 B microscope (Wetzlar, Germany) equipped with a
QICAM FAST 1394 (Surrey, British Columbia, Canada) dig-
ital camera using the 20 objective. To measure Sirius
red–positive staining, the examination area was chosen and
kept constant for all images, the same threshold was
applied to all images, and the integrated density for each
image was calculated by the program. An image of a blank
area of the slide was used for background correction. The
amount of collagen was expressed relative to the amount of
collagen in the saline-treated control group.Immunohistochemistry
Formalin-ﬁxed pancreatic tissue sections were pre-
treated to remove parafﬁn by standard methods. Endoge-
nous peroxidase activity was blocked by incubation in 3%
H2O2 at room temperature for 1 hour. Antigen retrieval
was performed by a high-temperature unmasking proce-
dure using citrate-based Antigen Unmasking Solution
(Vector Laboratories, Inc, Burlingame, CA). Immunologic
staining of the sections was conducted using Elite Uni-
versal Vectastain ABC kit (Vector Laboratories, Inc) ac-
cording to the manufacturer’s instructions. The antibody
to a-smooth muscle actin (a-SMA) was obtained from
Sigma (A2547; Sigma). The antibody to the av subunit was
obtained from Bioss (bs-2250R; Woburn, MA). The anti-
body to vimentin was obtained from Sigma (v-2258).
Secondary antibody peroxidase activity was detected with
diaminobenzidine solution (BioGenex, Fremont, CA), and
slides were counterstained with Hematoxylin Solution,Gill no. 3 (Sigma). Sections were dehydrated and mounted
with Permaslip Mounting Medium (Alban Scientiﬁc). Im-
ages were captured using a Leica DM4000 B microscope
equipped with a QICAM FAST 1394 digital camera using
the 20 or 40 objectives.
Immunoﬂuorescence
For immunoﬂuorescent staining of parafﬁn-embedded
tissues, parafﬁn removal and antigen retrieval was conduct-
ed as described for immunohistochemical staining. Anti–a-
SMA and antivimentin antibodies are described in the
Immunohistochemistry section. Secondary antibody conju-
gated with Cy3 for the detection of a-SMA–bound primary
antibody was obtained from Jackson Immuno–Research
(West Grove, PA) and secondary antibody conjugated with
ﬂuorescein isothiocyanate for detection of vimentin-bound
primary antibody was obtained from Sigma (F-9259). 40,6-
diamidino-2-phenylindole for nuclear counterstain was ob-
tained from ThermoScientiﬁc (Waltham, MA).
Images were captured using a Leica DM4000 B micro-
scope equipped with a QICAM FAST 1394 digital camera
using the 20 objective.
Apoptotic Cell Detection in Pancreatic Tissues
Apoptotic cells in pancreatic tissues were detected by
labeling and detecting DNA strand breaks by the terminal
deoxynucleotidyl transferase–mediated deoxyuridine tri-
phosphate nick-end labeling method using the ApopTag
Peroxidase Detection Kit (Millipore, Temecula, CA) accord-
ing to the manufacturer’s instructions. Stained apoptotic
cells with acinar morphology were counted by an experi-
enced pathologist masked to the treatment groups. Ten
high-power ﬁelds on each tissue section were used for
counting.
Western Blot
Western blot was conducted as we described previ-
ously27 using the following primary antibodies: a-SMA,
A2547, 1:1000 (Sigma); HDAC1, H3284, 1:1000 (Sigma);
phophorylated SMAD3 (p-SMAD3), ab52903, 1:1000
(Abcam, Cambridge, MA). Protein band intensities were
quantiﬁed using ImageJ software version 1.46 (National
Institutes of Health).
Plasma Amylase Activity
Amylase activity in mouse plasma was measured using
the Phadebas Amylase Test kit (Pharmacia Diagnostics AB,
Uppsala, Sweden) according to the manufacturer’s protocol,
and expressed as the fold-increase over the amylase activity
in the control saline-treated group of mice.
Hematologic Analysis
Cell counts from EDTA-anticoagulated, room-tempera-
ture, whole-blood samples were determined for each mouse
using an Abbot Cell-Dyn 3700 automated hematology
analyzer (GMI, Ramsey, MN).
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Using a Bead Beater (Biospec Products, Bartlesville, OK),
2-mm zirconia beads, and Eppendorf LoBind low-pro-
tein–binding tubes, fresh-frozen pancreases were
homogenized for 1 minute at 25 mg/mL in 50 mmol/L Tris-
HCl, pH 7.4, 20 mmol/L CaCl2, 0.05% Brij35, and 0.25%
Triton X-100 (Sigma-Aldrich, Saint Louis, MO). The homog-
enate was centrifuged at 18,000g for 5 minutes at 4C and
then placed on ice. The protein of each homogenate was
determined using the Pierce 660-nm Protein Assay Reagent
(ThermoFisher Scientiﬁc, Waltham, MA). Homogenate
samples were mixed with 2 Tris-glycine loading buffer
(ThermoFisher Scientiﬁc) and normalized to the sample with
the lowest protein content using water. Novex-Zymogram
precast 10% gels (ThermoFisher Scientiﬁc) were loaded
with 2 ng of matrix metalloproteinase (MMP)-2 (BioLegend,
San Diego, CA) and 9 ug of each of the pancreas homogenates.
Gels were run for 100 minutes at 125 V using Tris-glycine
sodium dodecyl sulfate running buffer (ThermoFisher Sci-
entiﬁc), followed by 3 successive 60-mL washes using 2.5%
Triton X-100 in water for 15 minutes. The gel was incubated
in 50 mmol/L Tris-HCl pH 7.4 with 10 mmol/L CaCl2 for 40
hours at 37C to activate the gelatinases, and then stained
with 0.1% Coomassie R-250 in 40% ethanol/10% acetic acid
for 1 hour at room temperature. The gel was de-stained in
25% ethanol/10% acetic acid for 45 minutes, followed by a
second destaining with 5% ethanol/7.5% acetic acid for 4
hours. The gel was imaged on a ChemiDoc XRSþ System (Bio-
Rad, Hercules, CA).
Isolation and Culture of Mouse Primary PSCs
Pancreata of ten 7- to 9-week-old C57BL/6J mice were
combined for mouse PSC (mPSC) isolation. mPSCs were
isolated using collagenase digestion and gradient centri-
fugation as we described previously.25 In one set of ex-
periments, isolated quiescent cells were used directly for
real-time PCR analysis. In another set of experiments,
isolated cells were plated on 100-mm plastic culture plates
and were maintained in 10% fetal bovine serum (FBS)
in Dulbecco’s modiﬁed Eagle medium (DMEM; Sigma-
Aldrich) with antibiotics (100 U penicillin, 0.1 mg/mL
streptomycin) in a humidifying incubator with a 5%
CO2–enriched atmosphere at 37C. PSCs were cultured for
9 days, plated on 24-well plates (Corning, Corning, NY),
and cultured for another 48 hours. Cells were serum-
starved for 48 hours and then treated either with 10%
FBS media or serum-free media for another 24 hours. RNA
was extracted using TRIzol reagent (Life Technologies)
and used for real-time quantitative PCR analysis.
Co-culture Bioassay to Measure TGFB Activation
Mink lung epithelial cells (MLECs) stably transfected
with a luciferase reporter gene with expression driven by a
portion of the plasminogen activator inhibitor promoter
were used to assay for the activation of latent TGFB
produced in co-culture with a PSC cell line. MLECs were
provided by Dr Rifkin (New York University, New York,
NY)34 and co-cultured rat PSC cell line LTC-14 was obtainedfrom Dr Sparmann (University of Rostock, Rostock, Ger-
many).35 MLECs were seeded at 1.5  104 cells/well on a
96-well, ﬂat-bottom, white-walled tissue culture plate
(Corning) in 50 mL of DMEM supplemented with 10% FBS,
penicillin, and streptomycin, and allowed to attach for 1
hour. LTC-14 cells were seeded on top of the MLECs in equal
volume at a density of 5  104 cells/well and were incu-
bated for 20 hours in a humidifying incubator with a 5%
CO2–enriched atmosphere at 37C. After incubation, media
was aspirated and cells were lysed in 50 mL of Glo Lysis
Buffer (Promega, Madison, WI) for 5 minutes. Next, an equal
volume of Bright-Glo-Reagent (Bright-Glo Luciferase Assay
System; Promega) was added to the lysis buffer and lucif-
erase activity was measured using a SpectraMax-L plate
reader (Molecular Devices, Sunnyvale, CA). Relative lucif-
erase activity was presented as the fold-increase over the
average of baseline luciferase activity (MLECs only). As
assay controls, TGFB neutralizing antibody (clone 1D11;
R&D Systems, Minneapolis, MN) or IgG1 isotype-matched
control antibody (clone 11711; R&D Systems) were added
at the start of the MLEC–LTC-14 co-culture to a ﬁnal con-
centration of 50 mg/mL. CWHM-12 and CWHM-96 control
compound were diluted in serum-free DMEM to obtain
the desired concentrations and added to MLEC–LTC-14 co-
cultures at the start of the experiment. Relative luciferase
activity values were imported into GraphPad Prism software
(La Jolla, CA) for generation of dose-response curves and
calculation of IC50 values.
Statistical Analysis
The nonparametric U test was used for statistical anal-
ysis of histologic measures of chronic and acute pancreatitis.
Statistical analysis of data for all other experiments was
performed using 1-way analysis of variance followed by a
2-tailed t-test (software version 3.1; SigmaStat, San Jose,
CA). For quantitative PCR results, DCT values were used for
statistical analysis, as recommended.36 Data are expressed
as means ± SEM.
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.
Results
Expression of RGD-Binding Integrin Subunits in
Mouse Pancreas in the Cerulein Model of
Pancreatic Fibrogenesis
Expression of RGD-binding integrin subunits was
analyzed in mouse pancreas by real-time quantitative PCR
after induction of pancreatic ﬁbrogenesis by repeated cer-
ulein treatment. Saline-treated mice served as controls. The
expression of mRNA for all RGD-binding integrin subunits
was detectable in the pancreas (Figure 1A). In control
pancreas, we detected prominent expression of av, a5, b1,
and b5 subunit mRNAs, which is consistent with the
possible expression of the following integrin heterodimers:
avb1, a5b1, and avb5. Relatively lower expression of a8, b6,
b3, and b8 mRNAs was detected, consistent with the
possible expression of integrins a8b1, avb6, avb3, and
avb8. Expression of all mRNA integrin subunits was induced
Figure 1. Expression of RGD-binding integrin subunits in mouse pancreas. Mice were subjected to repeated episodes of
cerulein (þ) or control saline (-) injections and killed on day 8 after the ﬁrst injection. One group of mice was treated with
CWHM-12 compound before cerulein and then throughout the studies as described in the Materials and Methods section. (A)
Expression of RGD-binding subunits in control and cerulein-treated pancreas was measured by real-time quantitative PCR,
normalized to the acidic ribosomal protein large P0, and depicted as the fold increase over the level of integrin b6 subunit
expression in the control group of mice. Data are expressed as means ± SEM; n ¼ 9. ***P < .001, *P < .05. (B) Representative
immunostaining of pancreatic sections with an av integrin subunit-speciﬁc antibody showed expression only in injured
pancreas, and was reduced dramatically with CWHM-12 treatment. (C) Expression of integrin aV mRNA measured by real-time
quantitative PCR and normalized to acidic ribosomal protein large P0 showed a reduction with CWHM-12 administration. Data
are shown as the fold increase over the level in control group of mice (no cerulein treatment). Data are expressed as means ±
SEM; n ¼ 9. ***P < .001.
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July 2016 Targeting Integrins in Chronic Pancreatitis 505signiﬁcantly with repetitive cerulein treatment. To investi-
gate whether RGD-binding integrins play a role in the
process of pancreatic ﬁbrogenesis, we evaluated the broad-
range RGD peptidomimetic integrin antagonist CWHM-12 in
the cerulein injury mouse model of CP. CP was induced by
repetitive administration of cerulein (days 1, 3, and 5), and
pancreatic injury then was assessed on day 8 as described in
the Materials and Methods section. CWHM-12 was delivered
by continuous infusion at a dose of 100 mg/kg/day using
minipumps implanted subcutaneously 3 days before the
ﬁrst cerulein treatment. At the end of the experiment, the
steady-state plasma concentration of CWHM-12 in each
mouse was determined by mass spectrometry analysis,
and corresponded to 9.1 ± 3.2 mg/mL (mean ± SD). Because
integrin subunit av is a component of most of the RGD-
binding integrins, the expression of this subunit was
analyzed in mouse pancreases at the protein level by
immunohistochemistry. Interestingly, we were able to
detect av integrin subunit only in injured cerulean-treatedFigure 2. Effect of CWHM-12 administration on the seve
Macroscopic images of the pancreas before and after prophyla
picture shows that repetitive cerulein treatments affect the size o
12 administration did not alter pancreatic atrophy signiﬁcantly. (
mice after the induction of CP by repetitive cerulein treatment
means ± SEM; n ¼ 9. *P < .001. (C) H&E staining of the pan
chitecture, dedifferentiation to tubular complexes, and interstitial
atrophy/dropout (see also Table 2). (D) Apoptotic cells in panc
mice. (E) Apoptotic cells with acinar morphology are increased
reduced with administration of CWHM-12, although this reduc
presented as fold increase over the numbers of apoptotic acina
n ¼ 3. **P < .01.pancreases; preventive administration of integrin antago-
nist CWHM-12 produced no detectable av expression
(Figure 1B). Induction of pancreatic integrin aV mRNA
expression induced by cerulein injury was similarly blocked
by prophylactic administration of CWHM-12 compound
(Figure 1C).Preventive Administration of Integrin Antagonist
CWHM-12 Attenuates Acinar Atrophy/Dropout in
the Mouse Model of Pancreatic Fibrogenesis
The ratios of pancreatic weight to mouse body weight, as
well as histologic changes, were evaluated to assess
pancreatic atrophy, inﬂammation, and ﬁbrosis. Pancreatic
weights were signiﬁcantly lower in the cerulein-treated
groups than in control mice, indicating signiﬁcant organ
atrophy with repetitive injury. CWHM-12 treatment did not
alter the effect of repetitive cerulein on pancreatic appear-
ance or pancreatic weight (Figure 2A and B, respectively).rity of cerulein-induced repetitive pancreatic injury. (A)
ctic administration of CWHM-12 compound. Representative
f the pancreas, indicating substantial organ atrophy. CWHM-
B) Pancreatic weight relative to total body weight in C57BL/6
showed substantial atrophy at day 8. Data are expressed as
creas from cerulein-treated mice shows disrupted acinar ar-
inﬂammation. CWHM-12 administration decreased acinar cell
reas are increased signiﬁcantly in cerulein-treated vs normal
signiﬁcantly in the cerulein-treated group. These cells were
tion did not reach statistical signiﬁcance (P ¼ .1). Data are
r cells in saline treated mice and expressed as means ± SEM;
Figure 2. (continued).
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staining. Slides were analyzed by an experienced pathologist
masked to treatment groups. Repetitive cerulein treatment
caused signiﬁcant morphologic alterations, including dis-
ruption of acinar cell architecture, inﬁltration with inﬂam-
matory cells, and development of tubular complexes.
Preventive administration of CWHM-12 had no statistically
signiﬁcant effect on the formation of tubular complexes or
inﬁltration of inﬂammatory cells. However, CWHM-12
application did decrease acinar cell atrophy/loss (Table 2),
which was associated with a more normal overall appear-
ance of the pancreatic tissue in H&E-stained sections
(Figure 2C). To assess if the observed effect of CWHM-12 on
acinar cell atrophy/loss was caused by decreased acinar
cell apoptosis, we performed terminal deoxynucleotidyl
transferase–mediated deoxyuridine triphosphate nick-endlabeling staining of apoptotic cells in pancreatic tissues
(Figure 2D). Apoptotic cells with acinar morphology were
counted by an experienced pathologist masked to the
treatment groups. Cerulein administration caused a signiﬁ-
cant increase in acinar apoptotic cells. CWHM-12 application
reduced acinar apoptotic cells in pancreas, although this
trend did not reach statistical signiﬁcance (Figure 2E).Preventive Administration of CWHM-12
Dramatically Reduced Pancreatic Collagen
Deposition in the Cerulein Mouse Model of
Pancreatic Fibrogenesis
Fibrosis in the pancreas was assessed by Sirius red
staining as a measure of collagen deposition (Figure 3A). In
control saline-treated mice, Sirius red staining was detected
Table 2.Effect of CWHM-12 Treatment on the Severity of
Cerulein-Induced CP
Histopathology No cerulein Cerulein
Cerulein þ
CWHM-12
Necrosis 0 ± 0 0 ± 0 0 ± 0
Acinar atrophy/loss 0 ± 0 3.63 ± 0.32 2.33 ± 0.47a
Tubular complexes 0 ± 0 3.38 ± 0.38 2.56 ± 0.41
Acute inﬂammation 0 ± 0 1.63 ± 0.18 1.25 ± 0.24
Chronic inﬂammation 0 ± 0 2.38 ± 0.26 2.13 ± 0.12
NOTE. Histopathology was scored blindly as described in the
Materials and Methods section. Higher values indicate
greater severity. Data are expressed as means ± SEM. n ¼ 10
mice per group.
aAcinar cerulein induction of CP was reduced signiﬁcantly by
CWHM-12 treatment (P < .05).
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cerulein treatment strongly increased interlobular and
periacinar staining, and this abnormal collagen deposition
was decreased strikingly by CWHM-12 continuously
administered before and during the injury-inducing
regimen. These changes were quantiﬁed with morpho-
metric image analysis (Figure 3B), which conﬁrmed signif-
icant reduction of collagen staining with CWHM-12
treatment. Because expression of collagen type Ia1(I)
(Col1a1) previously was reported to increase in pancreas of
rodents with induced CP as well as in human beings with
alcoholic pancreatitis,37 we analyzed the expression of
Col1a1 by real-time quantitative PCR. Pancreatic Col1a1
mRNA was induced signiﬁcantly by cerulein, and this in-
crease was prevented substantially by CWHM-12 treatment
(Figure 3C). Because collagen levels in tissue could be
affected by changes in degradation as well as synthesis, we
evaluated the activity of MMP by gelatin zymography. MMP
activity was increased signiﬁcantly in pancreas with cer-
ulein treatment, whereas CWHM-12-treated mice had
slightly less activity (Figure 3D). Mmp2 mRNA showed a
similar pattern of expression (Figure 3E).Preventive Administration of CWHM-12
Attenuates PSC Activation in the Cerulein Mouse
Model of Pancreatic Fibrogenesis
PSCs play a key role in extracellular matrix deposition
and pancreatic ﬁbrosis. In response to injury, PSCs develop
an activated myoﬁbroblast-like phenotype with increased a-
SMA accumulation. To investigate if CWHM-12 affects acti-
vation of PSCs, we measured pancreatic a-SMA expression
in our model. Pancreatic tissues from saline-treated control
mice contained only normal perivascular positive cells
and no interstitial a-SMA–positive staining cells, while
pancreatic tissues from cerulein-treated mice contained a-
SMA–positive cells in the periacinar spaces. CWHM-12
administration before and during the injury-inducing
regimen dramatically decreased the appearance of a-
SMA–positive staining (Figure 4A). To conﬁrm and quanti-
tate the results of a-SMA immunohistochemical staining, weconducted Western blot analysis of pancreatic extracts. This
showed that a-SMA expression was increased signiﬁcantly
in cerulein-treated mice and that CWHM-12 treatment fully
prevented it, resulting in a-SMA expression similar to
control mice (Figure 4B and C). To gain insight into the
mechanism of the CWHM-12–mediated decrease in a-
SMA–positive PSCs, we analyzed the effect of CWHM-12 on
total PSCs by measuring changes in the expression of
vimentin, which is expressed in both activated and quies-
cent PSCs. The expression of vimentin in normal saline-
treated mouse pancreases was undetectable, whereas
pancreases from cerulein-treated mice were highly stained
with vimentin antibody and coincided with anti–a-SMA
antibody staining (Figure 4D). Pancreases from CWHM-
12–treated mice had reduced but still signiﬁcant levels of
vimentin expression (Figure 4E); this suggests both
decreased PSC activation and activated PSC dropout may
account for the observed treatment-associated decrease in
activated PSCs. The expression of vimentin mRNA also was
assessed by real-time PCR, showing results similar to the
protein pattern of expression (Figure 4F).Preventive Administration of CWHM-12
Decreased Pancreatic TGFB Activation in
the Cerulein Mouse Model of Pancreatic
Fibrogenesis
p-SMAD3 measured by Western blot of pancreatic ex-
tracts was assessed as a measure of TGFB activation. This
showed that p-SMAD3 was increased in pancreases from
cerulein-treated mice, and that treatment with CWHM-12
prevented p-SMAD3 induction (Figure 5A).
We also assessed the expression of CTGF, because it is a
downstream target of TGFB and is recognized as a mediator
of the proﬁbrogenic actions of TGFB, including pancreatic
ﬁbrogenesis in human beings and animals.38 Real-time
PCR showed CWHM-12 administration prevented the
cerulein-induced up-regulation of this cytokine (Figure 5B).
Because TGFB is known to inhibit leukocyte proliferation
and activation, we performed hematologic analysis and
found that white blood cells were increased slightly in the
peripheral blood of compound-treated mice at study
termination (Table 3). This further supports the concept
that CWHM-12 treatment modulates TGFB function.Therapeutic Administration of CWHM-12
Alleviates Collagen Deposition and PSC
Activation in the Cerulein Mouse Model of
Pancreatic Fibrogenesis
To assess if administration of CWHM-12 still could have
an effect after ﬁbrosis already is present (therapeutic
mode), we implanted minipumps with CWHM-12 on day 5
of cerulein treatment, a time point when some ﬁbrosis
already has been established (Figure 6A), and then assessed
subsequent changes in ﬁbrosis in the pancreas on day 8.
Compound CWHM-96, the inactive control enantiomer of
CWHM-12, was used as a negative control. At the end of the
experiment, the steady-state plasma concentrations of the
Figure 3. Effect of CWHM-12 on pancreatic collagen content in cerulein-treated mice. (A) Collagen accumulation in the
pancreas assessed by Sirius red staining shows normal staining of perivascular and periductal stroma in the normal pancreas
(left), extensive periacinar ﬁbrosis in repetitive cerulein-treated animals (center), and substantial prevention of ﬁbrosis in
cerulein-treated animals that received CWHM-12 (right). (B and C) Data are shown as the fold increase over the level of the
control group of mice (no cerulein treatment) and expressed as means ± SEM; n ¼ 8. ***P < .001. (B) Quantiﬁcation of Sirius
red staining by morphometric analysis conﬁrms the prevention of collagen accumulation by CWHM-12 administration. (C)
Expression of Col1a1 mRNA measured by real-time quantitative PCR analysis and normalized to acidic ribosomal protein,
large, P0 shows prevention of the increased procollagen mRNA by CWHM-12 treatment. (D) Effects of CWHM-12 adminis-
tration on MMP enzyme activity in total pancreas. Gelatin zymography was performed with pancreas samples from normal
mice that received intraperitoneal saline injections, mice that received the intraperitoneal cerulein injections, and mice that
received cerulein injections while continuously treated with CWHM-12 delivered by osmotic minipumps. Puriﬁed recombinant
mouse MMP-2 (2 ng) was included as a positive control for zymography. (E) Expression of MMP-2 mRNA measured by real-
time quantitative PCR analysis and normalized to ribosomal protein, large, P0. Data are presented as the fold increase over the
level of the control group of mice (no cerulein treatment) and expressed as means ± SEM; n ¼ 8. ***P < .001.
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Figure 4. Effect of CWHM-12 on PSC activation in cerulein-treated mice. a-SMA was used as a marker of PSC activation.
(A) Immunostaining of pancreatic sections with a-SMA–speciﬁc antibody shows normal perivascular staining in control
pancreas (left), substantial periacinar staining after cerulein treatment (center), and prevention of PSC activation by CWHM-12
administration (right). (B) Representative Western blot of pancreatic extracts with a-SMA–speciﬁc antibody conﬁrmed the
differences seen histologically. Expression of a-SMA was normalized to the histone deacetylase 1 protein (HDAC1). (C)
Densitometric analysis of a-SMA expression. Data are expressed as means ± SEM; n ¼ 5. **P < .01. (D) Vimentin was used as
a marker of both quiescent and activated PSCs. Co-immunoﬂuorescent staining of pancreatic sections with vimentin and
a-SMA speciﬁc antibody was conducted as described in Materials and Methods. Representative picture demonstrates that
normal control pancreases do not have expression of vimentin or a-SMA except for the a-SMA expression in smooth muscle
cells surrounding blood vessel. After ceruein treatments, most of vimentin expressing PSC are a-SMA positive. (E) Immu-
nostaining of pancreatic sections with vimentin-speciﬁc antibody showed high expression in pancreas of cerulein-treated
mice, which was decreased partially with CWHM-12 administration. (F) Expression of vimentin mRNA measured by real-
time quantitative PCR analysis and normalized to ribosomal protein, large, P0 shows a similar pattern of vimentin expres-
sion. Data are shown as the fold increase over the level of the control group of mice (no cerulein treatment) and expressed as
means ± SEM; n ¼ 9. ***P < .001, **P < .01. DAPI, 4’,6-diamidino-2-phenylindole; Vim, vimentin.
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mass spectrometry. This conﬁrmed effective delivery of
both drugs with plasma concentrations of 6.1 ± 2.1 mg/mL
(mean ± SD) for CWHM-12 and 13.7 ± 5.5 mg/mL for
CWHM-96. Therapeutic CWHM-12 administration showed
effective reduction of collagen accumulation induced by
repetitive cerulein treatment by day 8 as assessed by Sirius
red staining whereas treatment with CWHM-96 did not
(Figure 6A). Results were quantiﬁed and conﬁrmed by
morphometric analysis (Figure 6B). Consistent with the
histologic ﬁndings, administration of CWHM-12 also signif-
icantly reduced cerulein-induced pancreatic Col1a1 mRNA
expression in the therapeutic mode. Treatment with the
inactive control compound CWHM-96 had no signiﬁcant
effect (Figure 6C). To evaluate if the decrease in collagen
accumulation was associated with decreased PSC activation,
we analyzed the expression of the activated PSC markera-SMA in the treatment groups by immunohistochemistry
and by real-time reverse-transcription PCR (Figure 6D and
6E). CWHM-12 treatment resulted in the nearly complete
disappearance of activated PSCs. Vimentin expression, a
marker of total PSCs, still was detected easily in this group,
but was reduced signiﬁcantly compared with the control
group.CWHM-12 Administration Does Not Change the
Parameters of Cerulein-Induced Acute
Pancreatic Injury in Mice
To evaluate the possibility that CWHM-12 administration
might inﬂuence the degree of acute pancreatic injury
induced by cerulein treatment, we evaluated its effect on
the following parameters of pancreatic injury in the acute
phase (9 hours after beginning injections): edema (ratio of
Figure 4. (continued).
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Figure 5. Effect of CWHM-12 on activated TGFB signaling in cerulein-treated mice. (A) Phosphorylation of SMAD3 was
assessed as a measure of TGFB activation. Representative Western blot of pancreatic extracts with p-SMAD3–speciﬁc an-
tibodies showed up-regulation with cerulein treatment, which was decreased to the level found in control pancreas after
administration of CWHM-12. The histone deacetylase 1 protein (HDAC1) was used as a loading control. (B) CTGF expression
was measured as a downstream target of TGFB signaling. CTGF mRNA expression was measured by real-time quantitative
PCR, normalized to the ribosomal protein, large, P0 and shown as the fold increase over the level of CTGF expression in the
control group of mice. CTGF expression was induced by repetitive cerulein administration and this increase was prevented by
administration of CWHM-12. Data are expressed as means ± SEM; n ¼ 9. ***P < .001.
July 2016 Targeting Integrins in Chronic Pancreatitis 511pancreatic weight to mouse weight), plasma amylase activ-
ity, and histologic changes assessed on H&E-stained sections
of the pancreas. Acute injury was induced as described in
the Materials and Methods section. Pancreatic edema and
plasma amylase levels increased considerably after acute
pancreatic injury, but CWHM-12 treatment did not have
signiﬁcant effects on these parameters (Figure 7A and B).
Histologic manifestations of acute pancreatitis (Figure 7C)
were assessed by blinded scoring of 4 slides per treatment
group at 9 hours after the ﬁrst cerulein injection and also
were not affected signiﬁcantly by CWHM-12 administration
(acinar necrosis, 2.0 ± 0 vs 2.0 ± 0; vacuolization, 1.5 ± 0.29
vs 1.25 ± 0.25; inﬂammatory cell inﬁltration, 2 ± 0 vs 1.0 ±
0.58; edema, 1 ± 0 vs 1 ± 0 in cerulein-treated and cerulein
plus CWHM-12–treated mice, respectively). Similar to our
ﬁndings in the chronic pancreatitis experiment, hematology
analysis showed no signiﬁcant changes in white blood cell
count between control and cerulein-treated groups,
although these were increased in the cerulein/CWHM-12




Control 7.1 ± 0.5 5.8 ± 0.4 (82) 1.2 ± 0.
Cerulein/veh 7.8 ± 0.5 6.4 ± 0.4 (81) 1.3 ± 0.
Cerulein/C 12 10.3 ± 0.7a 8.8 ± 0.7a (86) 1.3 ± 0.
NOTE. Groups of mice were subjected to either saline (contro
vehicle (veh) or CWHM-12 (C12) delivered as described in the t
SEM of cell counts (103/mL) determined using a Cell-Dyn 3700
percentage total white blood cells (WBCs) of lymphocytes (Lym
aP < .05 vs cerulein/veh.inhibition of RGD-binding integrins is antiﬁbrotic and not
anti-inﬂammatory, consistent with contrasting roles of
TGFB in these processes.Subunits of RGD-Binding Integrins Are
Expressed in Mouse Primary PSCs and Are
Induced With PSC Activation
To identify which RGD-binding integrins are expressed
speciﬁcally on PSCs and infer their potential roles in the
process of pancreatic ﬁbrogenesis, we ﬁrst analyzed the
expression of RGD-binding integrin subunits in quiescent
primary mPSCs that were isolated as described in the Ma-
terials and Methods section. Quiescent PSCs comprise only a
tiny portion (approximately 3%) of total pancreatic cells,
therefore we pooled pancreases from 10 C57BL/6 mice for
quiescent PSC isolation. By using quantitative real-time PCR,
we showed that mRNA encoding all subunits of the
RGD-binding integrins were present at varying levels in
primary mPSCs. Expression was most prominent for the av,Pancreatic Injury Studies
Acute model study
u WBC Lym Neu
1 (16) 3.3 ± 0.3 1.8 ± 0.1 (1.8) 1.5 ± 0.2 (44)
1 (17) 2.5 ± 0.6 1.0 ± 0.3 (1.0) 1.5 ± 0.4 (60)
1 (13) 6.2 ± 0.8a 3.0 ± 0.8a (3.0) 3.1 ± 0.2a (55)
l) or cerulein intraperitoneal injections, and were given either
ext for the chronic and acute models. Values are the mean ±
whole-blood analyzer. Numbers shown in parentheses are the
) and neutrophils (Neu).
Figure 6. Analysis of collagen content in the cerulein model of pancreatic ﬁbrogenesis after therapeutic administration
of CWHM-12. (A) Collagen content of the pancreas assessed by Sirius red staining on various days after cerulein treatment.
Saline-treated control mice showed no ﬁbrosis. Representative Sirius red pancreatic staining from 5 mice killed on day 5
relative to the ﬁrst cerulein treatment showed that some pancreatic ﬁbrosis already was established. Eight days into the
cerulein treatment regimen, further increase in ﬁbrosis was apparent. Therapeutic treatment with the CWHM-96 control
compound initiated on day 5 did not improve ﬁbrosis whereas CWHM-12 treatment from day 5 signiﬁcantly decreased ﬁbrosis
observed on day 8. (B and C) Data are shown as the fold increase over the level of the control group of mice (no cerulein
treatment). Data are expressed as means ± SEM; n ¼ 9. ***P < .001, *P < .05. (B) Quantiﬁcation of Sirius red staining by
morphometric analysis conﬁrms the changes seen visually. (C) Expression of Col1a1 mRNA measured by real-time quanti-
tative PCR analysis and normalized to acidic ribosomal protein, large, P0 showed a reduction in procollagen mRNA with
CWHM-12 treatment. (D) a-SMA was used as a marker of PSC activation and was analyzed by immunohistochemistry.
Representative picture of pancreatic sections with a-SMA–speciﬁc antibody shows blocking of cerulein-induced PSC acti-
vation by CWHM-12 treatment. (E) Expression of a-SMA and vimentin (Vim) mRNA measured by real-time quantitative PCR
analysis and normalized to ribosomal protein, large, P0. Data are shown as the fold increase over the level of the control group
of mice (no cerulein treatment) and are expressed as means ± SEM; n ¼ 9. ***P < .001, *P < .05.
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a8 subunits was extremely low (Figure 8A). In an inde-
pendent experiment, PSCs were isolated from 10 C57BL/6
mice and activated in culture as described in the
Materials and Methods section. To assess whether expres-
sion of integrin subunits changes with the state of PSC
activation, we deactivated PSCs in culture by serum star-
vation for 48 hours. This treatment is known to produce a
state of relative quiescence in cultured hepatic and
pancreatic stellate cells.39 After serum starvation, culture
media containing 10% FBS was re-introduced for 24 hours,
a treatment that increases the activation of PSCs and their
expression of a-SMA and proﬁbrogenic genes. We found
the integrin expression proﬁle in just-isolated primary
quiescent PSCs resembled the proﬁle of primary mPSCs
grown in culture and deactivated by serum withdrawal.
Activation of mPSCs was associated with a signiﬁcant in-
crease in expression of integrin subunits av, b1, and a5,
whereas the quiescent state was associated with greater b5
and b8 expression (Figure 8B). We also found expression of
a-SMA was increased signiﬁcantly with serum treatment,
conﬁrming activated status of mPSCs under this condition
(Figure 8C).CWHM-12 Treatment Blocks TGFB Activity
and Decreases Activation Markers of a PSC
Line In Vitro
To investigate whether the antiﬁbrotic mechanism of
CWHM-12 involves inhibition of TGFB activation speciﬁcally
by PSCs, we developed an in vitro system to study TGFB
activation in PSCs. The use of primary mouse PSCs for
in vitro studies is impractical because of extremely low yield
and a very limited numbers of passages can be performed
in culture. Therefore, we used an immortalized rat PSC line,
LTC-14, for this purpose. These immortalized cells have all
of the cardinal characteristics of activated PSCs such as
vimentin expression showing the mesenchymal origin of the
cells and a high level of a-SMA expression.35 To determine
if LTC-14 PSCs were capable of activating TGFB, we co-
cultured these cells with a well-known MLEC reporter line
that was designed for the sensitive detection of TGFB ac-
tivity.34 MLECs express a luciferase reporter gene under
the control of the plasminogen activator inhibitor 1 TGFB-
sensitive promoter. Co-culture of LTC-14 cells with the
MLEC reporter cell line led to a substantial increase in
luciferase activity (Figure 9A). Exogenous addition of a
TGFB-neutralizing antibody, but not an isotype-matched
Figure 6. (continued).
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luciferase activity, conﬁrming the speciﬁcity of this assay for
TGFB (Figure 9A). We then evaluated the effects of the
integrin antagonist compound CWHM-12 on TGFB activa-
tion. We found that CWHM-12 potently blocked TGFB acti-
vation by the PSC cell line with a mean IC50 value of
approximately 1.5 nmol/L (SD, 0.78; average, 4 independent
experiments). A representative inhibition curve is shown in
Figure 9B. In contrast, the negative control enantiomer
CWHM-96 had no effect on inhibition of TGF-b activation
by the PSCs in this assay, even at 1000-fold higher con-
centrations (data not shown). A separate study showed that
protein expression of the downstream TGFB target a-SMA,
also a marker of PSC activation, was reduced in cell culture
by incubation with CWHM-12 for 48 hours (Figure 9C and
D). MMP activity measured in cell lysates also was reduced
(Figure 9E and F). These changes align with our observa-
tions from in vivo studies described earlier.Discussion
Fibrosis is the major pathologic component of CP and
provides the background milieu for the development of
pancreatic cancer.1,40 No disease-speciﬁc treatment is
available. PSCs are the major source of extracellular matrix
(ECM) that accumulates during pancreatic ﬁbrogenesis.4,41
It now is well established that TGFB and its downstream
effector CTGF are the main cytokines responsible forstimulating the synthesis and secretion of ECM proteins by
PSCs.5 The pleotropic cytokine TGFB is regulated at many
levels but probably the most important step in TGFB regu-
lation is its extracellular activation.7 The mechanism of
TGFB activation in pancreatic ﬁbrotic diseases is unknown.
Recent data have indicated that in many organ injury states
that lead to ﬁbrosis, members of the RGD-binding integrin-
receptor family appear to be the primary mediators of latent
TGFB activation in vivo. 9–11 Besides activation of TGFB,
RGD-binding integrins mediate other functions such as
angiogenesis or ECM remodeling, as well as the migration of
many cell types, which we speculate also are likely to be
important at various stages of the initiation, development,
maintenance, and resolution of ﬁbrosis.42,43
In this study, we evaluated the role of RGD-binding
integrins in the development of pancreatic ﬁbrogenesis.
By using quantitative real-time PCR analysis, we showed
the expression of the subunits of RGD-binding integrins in
the mouse pancreas and showed all were increased after the
induction of CP. Expression of b6 and a8 subunits was very
low even after CP induction. Because these subunits only
form heterodimers with the av and b1 subunits, respec-
tively, these data suggest integrins avb6 and a8b1 are not
prominent in either the normal or injured pancreas. These
data would not preclude the possibility of their signiﬁcant
expression in small subpopulations of the total cells in
pancreas. Expression of the av integrin subunit was easily
detectable at the mRNA and protein levels in ﬁbrotic but
Figure 7. Effect of CWHM-12 administration on the severity of cerulein-induced acute pancreatic injury. (A) CWHM-12
administration did not affect pancreatic edema (measured as the ratio of pancreatic weight to body weight) in cerulein-treated
mice. Data are expressed as means ± SEM; n ¼ 5. ***P < .001. (B) CWHM-12 administration did not affect plasma amylase
levels induced by cerulein treatment. Data are expressed as means ± SEM; n ¼ 5. ***P < .001. (C) Representative (of 4 mice
per group) H&E staining of mouse pancreatic sections. Pancreas from cerulein-treated mice showed acute injury including
vacuolization, inﬂammatory cell inﬁltration, necrosis, and edema. CWHM-12 did not affect these parameters (see the Results
section for quantitation).
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undetectable level by treatment with CWHM-12. The av
subunit forms heterodimers with multiple b subunits to
form several RGD-binding integrins, so the compound has
the potential to affect functions of all of these expressed
integrins simultaneously.
Our pharmacologic inhibitory approach based on the use
of the potent synthetic nonpeptide broad-spectrum RGD
peptidomimetic compound CWHM-12 allows direct func-
tional evaluation of the importance of the whole group of
RGD-binding integrins that are expressed in pancreas, both
in normal mice and in mice with hyperstimulation-induced
acute or chronic pancreatitis. As shown previously,
CWHM-12 has high potency in blocking in vitro ligand
binding to 4 of the TGFB-activating av subunit-containing
integrins (avb1, avb3, avb6, and avb8), and also has mod-
erate potency against the TGFB-activating integrin avb5.11
Our previous data also showed that CWHM-12 is a highly
potent inhibitor of a5b1, an RGD-binding integrin, which
has not been implicated in TGFB activation, but has known
involvement in processes that are associated with ﬁbrosissuch as angiogenesis, cellular migration, and CTGF binding.
We found that except for a slight prevention of cerulein-
induced acinar cell atrophy/loss, CWHM-12 administration
did not affect acinar cell morphology or inﬂammatory cell
inﬁltration. However, it did dramatically suppress pancre-
atic ﬁbrosis when administered prophylactically in the
cerulein-induced CP model. We speculate that the modest
improvement in acinar cell atrophy/loss could result from a
decreased rate of acinar cell apoptosis because previous
studies have shown that apoptosis plays an essential role in
acinar cell loss in chronic pancreatitis,44 and it also was
shown that inhibition of TGFB1 action protects acinar cells
from apoptosis in the cerulein model of chronic pancreatic
injury.22 Indeed, our analysis showed a signiﬁcant increase
in acinar cell apoptosis in the cerulein-treated group vs
normal pancreas, and a trend toward reduction in apoptotic
cells with CWHM-12 treatment. Pancreatic collagen content
measured by Sirius red staining was decreased by more
than 80% relative to vehicle-treated mice. This degree of
ﬁbrosis prevention in the CP model exceeds that seen in
our similar recent studies in which preventive CWHM-12
Figure 8. Expression of RGD-binding integrin subunits in mouse primary PSCs. (A) Primary mouse quiescent PSCs were
isolated as described in the Materials and Methods section and subjected to real-time reverse-transcription PCR to detect the
expression of mRNA encoding integrin subunits. Expression is shown as the fold increase over the level of b6 subunit. (B and
C) Data are expressed as means ± SEM; n ¼ 3. ***P < .001, **P < .01, *P < .05. (B) Primary mPSCs were expanded in culture
as described in the Results section, and integrin subunit expression was compared between serum-deprived PSCs and
serum-activated PSC growth conditions. Integrin subunit mRNA expression shown as the fold increase over the level of a8
subunits in the serum free–treated cells showed induction of the av, a1, and b1 subunits with culture activation. (C) Decreased
a-SMA mRNA expression in PSCs after serum deprivation supports de-activated status of PSC.
July 2016 Targeting Integrins in Chronic Pancreatitis 515delivered at the same continuous dose in a mouse model of
liver ﬁbrosis produced less than a 50% decrease in collagen
content.11 CWHM-12–mediated reduction in pancreatic
collagen content was accompanied by decreased PSC acti-
vation as assessed by expression analysis of a-SMA, the
principal marker of PSC activation. CWHM-12 administra-
tion completely prevented an increase in a-SMA expression
in the pancreas after cerulein injury, whereas in the previ-
ous mouse model of liver ﬁbrosis, a-SMA expression was
decreased by only approximately 35%.11 Animals receiving
the compounds by continuous infusion from minipumps
consistently achieved steady-state plasma levels that far
exceeded the concentrations that we showed fully inhibit
integrin-mediated TGFB activation by PSCs and other cells
in vitro. Therefore, we consider it unlikely that observed
differences in efﬁcacy between models are associated with
variations in pharmacokinetic exposure. Instead, the more
potent effect of CWHM-12 in preventing pancreatic
compared with liver ﬁbrosis supports the concept that the
roles of RGD-binding integrins in ﬁbrosis are to some extent
tissue-, cell-, and/or injury-speciﬁc.10
Our observation that cerulein-injured pancreases in
CWHM-12–treated mice contained almost no detectable a-
SMA–positive PSCs could be owing to severe blockade of
PSC activation, severe loss of activated PSCs, or a combi-
nation of these mechanisms. CWHM-12 treatment did not
completely prevent the appearance of vimentin-positive
cells. This suggests that PSCs proliferated in response to
injury but were unable to complete their activation program
owing to a lack of sufﬁcient TGFB signaling. However, we
hypothesize the drug also promotes loss of activated PSCs
that do form because the level of vimentin-stained cells was
clearly lower in cerulein-injured pancreases with CWHM-12
treatment.
Matrix metalloproteinase expression and activity were
decreased by CWHM-12 treatment in cerulein-injured mice,
suggesting that a reduction in collagen synthesis, not
increased collagen degradation, is accountable for reduced
ﬁbrosis. This result may stem from the near-completeabsence in the drug-treated samples of activated PSCs, a
potentially rich source of such proteases.45 Future studies
will be needed to elucidate more precisely the mechanism of
the observed effect.
Prophylactic studies are useful to provide initial proof-
of-concept and to help determine the maximal impact of
targeting a pathway from the earliest stages of develop-
ment of the pathology. However, therapeutic administra-
tion studies provide a more appropriate context to assess
the potential for clinical relevance with respect to
arresting or reversing established ﬁbrosis. We found that
CWHM-12, but not CWHM-96 control treatment, signiﬁ-
cantly reduced ﬁbrosis even after some ﬁbrosis already
had been established. The R-enantiomer of CWHM-12,
CWHM-96, is an excellent negative control comparator
because it differs in structure from CHWM-12 only in the
orientation of its carboxyl (CO2H) group and was at least
100-fold less active than CWHM-12 in all integrin
assays.11
Our data showing that SMAD3 phosphorylation, together
with transcription of TGFB-inducible genes Col1a1 and
CTGF,38,46 was decreased signiﬁcantly by preventive
CWHM-12 administration are consistent with TGFB activa-
tion as a probable primary mechanism through which RGD-
binding integrins regulate pancreatic ﬁbrogenesis. However,
to rule out the possibility that the efﬁcacy was secondary to
a possible compound-mediated effect in decreasing the
severity of the initial acute pancreatic injury that precedes
and serves as a stimulus for ﬁbrosis development, we
evaluated the effect of CWHM-12 treatment in acute
pancreatic injury. No signiﬁcant differences in acute injury
responses were found between CWHM-12 and vehicle-
treated mice assessed by analyzing changes in pancreatic
edema, levels of plasma amylase activity, and histologic
evaluation after one cerulein treatment (consisting of 6
hourly injections). The data showing that RGD-binding
integrins are not implicated in the initial injury suggest
potential future clinical utility for antagonists will be in
treatment of ﬁbrosis associated with chronic pancreatitis.
Figure 9. Effect of CWHM-12 administration on TGFB activity and activation markers of a PSC line in vitro. (A) Co-culture
of TGFB reporter MLECs with LTC-14 PSCs increased luciferase reporter activity, indicating activation of latent TGFB.
Neutralizing TGFB antibody, but not an isotype control IgG1 antibody, inhibited this activation, conﬁrming that the observed
increase in luciferase activity is TGFB dependent. Data are shown as the fold increase over the level of luciferase activity in
MLECs alone and expressed as means ± SEM; n ¼ 3. ***P < .001. (B) Concentration-dependent inhibition of integrin-mediated
TGFB activation in LTC-14 by CWHM-12. The IC50 value calculated from the inhibition curve for CWHM-12 was 2.5 nmol/L.
Luciferase activity on the graph is presented as the fold increase over the luciferase activity of MLECs cultured alone. Data are
shown as means ± SEM; n ¼ 3. (C). Representative picture of a-SMA protein expression in LTC-14 detected by Western blot
showed a decrease in a-SMA expression with CWHM-12 treatment. (D) Densitometry analysis of a-SMA expression
normalized to GAPDH. (E) Effect of CWHM-12 administration on gelatinase activity of LTC-14 PSCs. Gelatinase activity was
detected by zymography. Puriﬁed recombinant MMP-2 (2 ng) was included as a positive control. (F) Densitometry analysis of
MMP activity. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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on myoﬁbroblasts was implicated previously in the devel-
opment of ﬁbrosis in the mouse liver, lung, and kidney.11 As
a ﬁrst step in understanding the mechanism of integrin ef-
fects on TGFB activation in pancreatic cell types, we
analyzed the expression of RGD-binging integrin subunits on
primary PSCs, the major cell type responsible for ECM
deposition in this organ. We detected the expression of all
subunits of the RGD-binding integrins in primary quiescent
mPSCs. The expression of integrin subunits b6 and a8 was
extremely low. This ﬁnding is consistent with those of other
investigators showing that ﬁbroblasts are largely devoid of
avb6 integrin.47,48 Interestingly, the expression of a5, av,
and b1 subunits was induced with mPSC activation. The
expression of a5b1 was reported previously in rat PSCs and
was shown to be involved in CTGF signaling.43 To evaluate
whether RGD-binding integrins play a role in TGFB activa-
tion by PSCs, we developed a co-culture assay using a
characterized PSC cell line and a widely used TGFB reporter
cell line. We showed that the PSC line could robustly acti-
vate endogenously produced TGFB, and that CWHM-12, but
not the control CWHM-96, compound potently blockedTGFB activation in this assay. This ﬁnding strongly supports
a mechanism of TGFB activation by PSC-expressed
RGD-binding integrins as a major mediator of pancreatic
ﬁbrogenesis.References
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